Drug Database
Back to search

Netherlands· NL-6358993e71f0

Tysabri 300 mg (20 mg/ml) concentraat voor oplossing voor injectie, concentraat voor oplossing voor injectie

A natalizumab product containing natalizumab, registered in Netherlands by Biogen Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC L04AG03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTysabri 300 mg (20 mg/ml) concentraat…ATCL04AG03REGISTER NO.NL-6358993e71f0PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about natalizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Natalizumab is registered in 11 of 19 countries.

Countries holding a registration under ATC L04AG03 (natalizumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search natalizumab products by name

Natalizumab · ATC L04AG03

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NATALIZUMAB
Manufacturer
Biogen Netherlands B.V.
Country
Netherlands (NL)
ATC code
L04AG03
ATC class
Natalizumab
Defined daily dose
10 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/06/346

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

323 interactions on record for natalizumab.

Graded by severity as the source publishes them — 301 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check natalizumab against other medicinesHow interaction checks work

Natalizumab · interactions on record

323 records

  • 301 severe
  • 15 moderate
  • 7 minor

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Natalizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All natalizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tyruko, Tysabri
  • Liechtenstein · Tyruko, Tysabri
  • Norway · Tyruko, Tysabri

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d90a3a15-e5ca-4532-a2d1-030f0871c2d4
GET /v1/drugs/d90a3a15-e5ca-4532-a2d1-030f0871c2d4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Natalizumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp72538",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "POLYSORBAAT 80 (E 433)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "NATALIZUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2006/06/27",
  "procedure_number": "EMEA/H/C/000603",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/06/346",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about natalizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console